2005PubMedRequires access

Potential prognostic value of circulating levels of vascular endothelial growth factor-A in patients with gastric cancer.

Shigang Ding, San-ren Lin, Xiuyun Dong, Xueling Yang, Hengy Qu, Shu‐Mei Huang, Wenjing Liu, Liya Zhou, Donghui Liu

Open publisher page 17 citations

Abstract

OBJECTIVE: The aim of this study was to evaluate the potential prognostic value of the circulating levels of vascular endothelial growth factor-A (VEGF-A) in patients with gastric cancer. MATERIALS AND METHODS: An ELISA was used to quantify the serum and plasma levels of VEGF-A in 135 patients with gastric cancer and 48 controls with benign gastric diseases diagnosed by gastroendoscopy and histology of the biopsied specimens. Serum VEGF-A levels were assayed in controls (n = 10) and patients with gastric cancer (n = 10) prior to surgery. Further samples from 16 patients with gastric cancer, 3 weeks after tumour excision, were collected. RESULTS: VEGF-A levels were significantly higher in both serum and plasma from patients with gastric cancer than those from the controls (serum: 342.1 pg/ml vs. 80.0 pg/ml, p < 0.01; plasma: 74.1 pg/ml vs. 23.7pg/ml, p < 0.01). In both cancer patients prior to surgery and controls, serum VEGF-A levels appeared to be unchanged over a 7-day period. However, examination of paired samples from 16 cancer patients collected prior to surgery and 3 weeks post-surgery showed that tumor excision resulted in a significant decrease in VEGF-A levels (Paired t-test, t = 5.4, p < 0.0001). CONCLUSION: Serum and plasma VEGF-A levels were significantly higher in patients with gastric cancer than in the controls. Serum VEGF-A levels correlated with tumour burden, as VEGF-A levels were significantly lowered following tumour excision in patients with gastric cancer.

About this research paper

What this paper is about

OBJECTIVE: The aim of this study was to evaluate the potential prognostic value of the circulating levels of vascular endothelial growth factor-A (VEGF-A) in patients with gastric cancer. MATERIALS AND METHODS: An ELISA was used to quantify the serum and plasma levels of VEGF-A in 135 patients with gastric cancer and 48 controls with benign gastric diseases diagnosed by gastroendoscopy and histology of the biopsied specimens. Serum VEGF-A levels were assayed in controls (n = 10) and patients with gastric cancer (n = 10) prior to surgery. Further samples from 16 patients with gastric cancer, 3 weeks after tumour excision, were collected. RESULTS: VEGF-A levels were significantly higher in both serum and plasma from patients with gastric cancer than those from the controls (serum: 342.1 pg/ml vs. 80.0 pg/ml, p < 0.01; plasma: 74.1 pg/ml vs. 23.7pg/ml, p < 0.01). In both cancer patients prior to surgery and controls, serum VEGF-A levels appeared to be unchanged over a 7-day period. However, examination of paired samples from 16 cancer patients collected prior to surgery and 3 weeks post-surgery showed that tumor excision resulted in a significant decrease in VEGF-A levels (Paired t-test, t = 5.4, p < 0.0001). CONCLUSION: Serum and plasma VEGF-A levels were significantly higher in patients with gastric cancer than in the controls. Serum VEGF-A levels correlated with tumour burden, as VEGF-A levels were significantly lowered following tumour excision in patients with gastric cancer.

Why it matters

OpenAlex reports 17 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: The aim of this study was to evaluate the potential prognostic value of the circulating levels of vascular endothelial growth factor-A (VEGF-A) in patients with gastric cancer. MATERIALS AND METHODS: An ELISA was used to quantify the serum and plasma levels of VEGF-A in 135 patients with gastric cancer and 48 controls with benign gastric diseases diagnosed by gastroendoscopy and histology of the biopsied specimens. Serum VEGF-A levels were assayed in controls (n = 10) and patients with gastric cancer (n = 10) prior to surgery. Further samples from 16 patients with gastric cancer, 3 weeks after tumour excision, were collected. RESULTS: VEGF-A levels were significantly higher in both serum and plasma from patients with gastric cancer than those from the controls (serum: 342.1 pg/ml vs. 80.0 pg/ml, p < 0.01; plasma: 74.1 pg/ml vs. 23.7pg/ml, p < 0.01). In both cancer patients prior to surgery and controls, serum VEGF-A levels appeared to be unchanged over a 7-day period. However, examination of paired samples from 16 cancer patients collected prior to surgery and 3 weeks post-surgery showed that tumor excision resulted in a significant decrease in VEGF-A levels (Paired t-test, t = 5.4, p < 0.0001). CONCLUSION: Serum and plasma VEGF-A levels were significantly higher in patients with gastric cancer than in the controls. Serum VEGF-A levels correlated with tumour burden, as VEGF-A levels were significantly lowered following tumour excision in patients with gastric cancer.

Key concepts: Medicine, Vascular endothelial growth factor, Cancer, Internal medicine, Gastroenterology, VEGF receptors, Histology, Pathology

Related papers

Back to paper searchBrowse research topicsOriginal source
Potential prognostic value of circulating levels of vascular endothelial growth factor-A in patients with gastric cancer. — Research Paper | ScholarLens